Molecular Basis of Loss Aversion

Zhejiang University

Status: Enrolling

Conditions: Healthy

Treatments: Drug: single-dose placebo, single-dose madopar, and single-dose propranolol by order; Drug: single-dose madopar, single-dose propranolol, and single-dose placebo by order; Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by order; Drug: single-dose placebo, single-dose propranolol, and single-dose madopar by order; Drug: single-dose propranolol, single-dose placebo, and single-dose madopar by order; Drug: single-dose propranolol, single-dose madopar, and single-dose placebo by order

Study type: Interventional

Funder types: Other

Identifiers

NCT06034158

20230496

Details and patient eligibility

About

The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.

Enrollment: 60 estimated patients

Sex: All

Ages: 25 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age 25-40 years old (including boundary value).
2. Elementary school education or above, able to understand the research content.
3. Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.

Exclusion criteria

1. Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
2. Family history of genetic diseases.
3. Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
4. History of alcohol/drug dependence.
5. Lactating women.
6. The cardiopulmonary function test results are poor.
7. Have ever taken madopar or propranolol for medical use.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

60 participants in 6 patient groups

madopar-propranolol-placebo

Other group

Description:

In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions.

Treatment:

Drug: single-dose madopar, single-dose propranolol, and single-dose placebo by order

madopar-placebo-propranolol

Other group

Description:

In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions.

Treatment:

Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by order

propranolol-madopar-placebo

Other group

Description:

In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions.

Treatment:

Drug: single-dose propranolol, single-dose madopar, and single-dose placebo by order

propranolol-placebo-madopar

Other group

Description:

In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions.

Treatment:

Drug: single-dose propranolol, single-dose placebo, and single-dose madopar by order

placebo-propranolol-madopar

Other group

Description:

In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions.

Treatment:

Drug: single-dose placebo, single-dose propranolol, and single-dose madopar by order

placebo-madopar-propranolol

Other group

Description:

In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions.

Treatment:

Drug: single-dose placebo, single-dose madopar, and single-dose propranolol by order